Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study)-Reference-Cited by-同舟云学术

Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study)

Published:2017-03 Issue:2 Volume:28 Page:152-162
ISSN:0957-5235
Container-title:Blood Coagulation & Fibrinolysis
language:en
Short-container-title:

Author:

Lissitchkov Toshko J.,Buevich Evgeny,Kuliczkowski Kazimierz,Stasyshyn Oleksandra,Cerqueira Monica Hermida,Klukowska Anna,Joch Christine,Seifert Wilfried

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hematology,General Medicine

Reference32 articles.

1. von Willebrand factor: from cell biology to the clinical management of von Willebrand's disease;Vischer;Crit Rev Oncol Hematol,1999

2. Treatment of von Willebrand's disease;Mannucci;N Engl J Med,2004

3. Diagnosis and management of von Willebrand disease;Federici;Haemophilia,1999

4. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands’ diseases;Mannucci;Lancet,1977

5. How I treat patients with von Willebrand disease;Mannucci;Blood,2001

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factor VIII stimulants and other novel therapies for the treatment of von Willebrand disease: what’s new on the horizon?;Expert Opinion on Pharmacotherapy;2024-07-23

2. A Systematic Review of Efficacy and Safety of Plasma-Derived von Willebrand Factor/Factor VIII Concentrate (Voncento) in von Willebrand Disease;Thrombosis and Haemostasis;2024-01-25

3. An open‐label, multi‐centre, post‐marketing study to assess the efficacy and safety of a plasma‐derived VWF/FVIII concentrate in patients with von Willebrand disease;Haemophilia;2023-11-29

4. Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results;Blood;2022-07-14

5. Multifaceted pathomolecular mechanism of a VWF large deletion involved in the pathogenesis of severe VWD;Blood Advances;2022-02-07